APA (7th ed.) Citation

Tassone, P., Di Martino, M. T., Arbitrio, M., Fiorillo, L., Staropoli, N., Ciliberto, D., . . . Caracciolo, D. (2023). Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: A first-in-human, phase 1, open-label, dose-escalation study. Journal of Hematology & Oncology, 16(1), 1. https://doi.org/10.1186/s13045-023-01468-8

Chicago Style (17th ed.) Citation

Tassone, Pierfrancesco, et al. "Safety and Activity of the First-in-class Locked Nucleic Acid (LNA) MiR-221 Selective Inhibitor in Refractory Advanced Cancer Patients: A First-in-human, Phase 1, Open-label, Dose-escalation Study." Journal of Hematology & Oncology 16, no. 1 (2023): 1. https://doi.org/10.1186/s13045-023-01468-8.

MLA (9th ed.) Citation

Tassone, Pierfrancesco, et al. "Safety and Activity of the First-in-class Locked Nucleic Acid (LNA) MiR-221 Selective Inhibitor in Refractory Advanced Cancer Patients: A First-in-human, Phase 1, Open-label, Dose-escalation Study." Journal of Hematology & Oncology, vol. 16, no. 1, 2023, p. 1, https://doi.org/10.1186/s13045-023-01468-8.